Lipopeptide Laur-CKK-NH2 dimer preserves daptomycin susceptibility and enhances its activity against Enterococcus faecalis

Journal of Antimicrobial Chemotherapy

Volumn 66, Issue 4, 2011, Pages 859-862

  Cirioni, Oscar ^a   Kamysz, Elzbieta ^b   Ghiselli, Roberto ^a   Kamysz, Wojciech ^c   Silvestri, Carmela ^a   Orlando, Fiorenza ^d   Rimini, Massimiliano ^a   Brescini, Lucia ^a   Gabrielli, Eleonora ^a   Marchionni, Elisa ^a   Rocchi, Marco ^e   Provinciali, Mauro ^d   Guerrieri, Mario ^a   Giacometti, Andrea ^a  

^a UNIVERSITÀ POLITECNICA DELLE MARCHE   (Italy)

^b UNIVERSITY OF GDA SK   (Poland)

^c MEDICAL UNIVERSITY OF GDANSK   (Poland)

^d INRCA   (Italy)

^e UNIVERSITY OF URBINO   (Italy)

Author keywords

E. faecalis; Enterococci; Sepsis

Indexed keywords

CYSTEINE; DAPTOMYCIN; DIMER; LAURIC ACID; LAURIC ACID CYSTEINYLLYSYLLYSINAMIDE DIMER; LIPOPEPTIDE; LYSINE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBACTERIAL ACTIVITY; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL STRAIN; BLOOD CULTURE; CONTROLLED STUDY; DRUG POTENTIATION; ENTEROCOCCAL INFECTION; ENTEROCOCCUS FAECALIS; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MALE; MINIMUM INHIBITORY CONCENTRATION; MOUSE; NONHUMAN; OUTCOME ASSESSMENT;

ANIMALS; DAPTOMYCIN; DRUG INTERACTIONS; DRUG THERAPY, COMBINATION; ENTEROCOCCUS FAECALIS; GRAM-POSITIVE BACTERIAL INFECTIONS; LIPOPEPTIDES; MICE; MICROBIAL SENSITIVITY TESTS; TREATMENT OUTCOME;

EID: 79952789618     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkr001     Document Type: Article

References (10)

1. Wisplinghoff H, Bischoff T, Tallent SM et al. Nosocomial bloodstream infections in US hospitals: analysis of 24,179 cases from a prospective nationwide surveillance study. Clin Infect Dis 2004; 39: 309-17.
2. Eliopoulos GM. Microbiology of drugs for treating multiply drug-resistant Gram-positive bacteria. J Infect 2009; 59 Suppl 1: S17-24.
3. Canton R, Ruiz-Garbajosa P, Chaves RL et al. A potential role for daptomycin in enterococcal infections: what is the evidence? J Antimicrob Chemother 2010; 65: 1126-36.
4. Steenbergen JN, Mohr JF, Thorne GM. Effects of daptomycin in combination with other antimicrobial agents: a review of in vitro and animal model studies. J Antimicrob Chemother 2009; 64: 1130-8.
5. Hancock REW, Scott MG. The role of antimicrobial peptides in animal defences. Proc Natl Acad Sci USA 2000; 97: 856-61.
6. Avrahami D, Shai Y. A new group of antifungal and antibacterial lipopeptides derived from non-membrane active peptides conjugated to palmitic acid. J Biol Chem 2004; 279: 12277-85.
7. Cirioni O, Silvestri C, Ghiselli R et al. Experimental study on the efficacy of combination of α-helical antimicrobial peptides and vancomycin against Staphylococcus aureus with intermediate resistance to glycopeptides. Peptides 2006; 27: 2600-6.
8. Chan WC, White PD. Fmoc Solid Phase Peptide Synthesis. A Practical Approach. Oxford: Oxford University Press, 2000.
9. National Committee for Clinical Laboratory Standards. Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria That Grow Aerobically-Sixth Edition: Approved Standard M7-A6. NCCLS, Wayne, PA, USA, 2003.
10. Eliopoulos GM, Moellering RC Jr. Antimicrobial combinations. In: Lorian V, ed. Antibiotics in Laboratory Medicine. Baltimore, MD: Williams & Wilkins, 1996; 330-93.